Physician profile
Ralph Oiknine
NPI 1255365581
$144,324.36
in general payments reported to CMS, 2019-2025
53 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $19K · 2021: $29K · 2022: $19K · 2023: $3,331 · 2024: $22K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $4,463 · Travel and Lodging: $2,017 · Consulting Fee: $450 · Gift: $59.40 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,656.25 |
| Food and Beverage | $4,462.91 |
| Travel and Lodging | $2,016.58 |
| Consulting Fee | $450.00 |
| Gift | $59.40 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33,248.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $29,400.92 | 2019-2023 | Farxiga |
| Abbvie INC. | $21,476.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $18,192.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,807.59 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $8,288.78 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Insulet Corporation | $5,026.94 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $2,830.27 | 2019-2025 | |
| Valeritas, INC. | $2,296.18 | 2019 | |
| Medtronic, INC. | $1,986.94 | 2021-2025 | Minimed 780g, Inceptiv, Intellis Adaptivestim |
| Abbott Laboratories | $1,605.27 | 2019-2025 | Freestyle Libre 3 |
| Senseonics, Incorporated | $1,370.00 | 2019-2025 | Eversense |
| Ascensia Diabetes Care US INC. | $771.32 | 2021-2025 | |
| Sequel Med Tech, LLC | $319.24 | 2025 | Twiist |
| Dexcom, INC. | $271.07 | 2019-2021 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $255.98 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Mannkind Corporation | $208.59 | 2023-2025 | Afrezza |
| Novartis Pharmaceuticals Corporation | $158.70 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.49 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $139.52 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $126.23 | 2021-2025 | Korlym |
| Amgen INC. | $122.60 | 2019-2025 | Repatha, Tepezza, Evenity |
| Tandem Diabetes Care, INC. | $114.75 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $101.35 | 2020-2023 | Steglatro |
| Radius Health, INC. | $96.35 | 2024-2025 | Tymlos |
| Amarin Pharma, INC. | $81.37 | 2020-2021 | |
| Lifescan, INC. | $66.99 | 2019-2021 | |
| Intuity Medical INC | $63.34 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Antares Pharma, INC. | $61.81 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $59.98 | 2024-2025 | Strensiq |
| Ibsa Pharma INC. | $55.53 | 2022-2025 | Licart, Flector, Tirosint |
| Kyowa Kirin, INC. | $52.67 | 2023-2025 | Crysvita |
| Nevro Corp. | $46.43 | 2022-2023 | Senza |
| Horizon Therapeutics Plc | $45.16 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $43.14 | 2024-2025 | Yorvipath |
| Medtronic Minimed, INC. | $37.08 | 2019-2020 | |
| Pfizer INC. | $34.97 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $34.14 | 2022-2023 | Isturisa, Signifor Lar |
| Amphastar Pharmaceuticals, INC. | $33.10 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $32.97 | 2023-2024 | Inpefa |
| Endo Pharmaceuticals INC. | $29.09 | 2021 | |
| Zealand Pharma US, INC. | $22.54 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.05 | 2020 | |
| Halozyme INC | $17.61 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $17.08 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.74 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $16.38 | 2023 | Prehevbrio |
| Rgh Enterprises LLC | $16.10 | 2025 | |
| Eusa Pharma (US) LLC | $15.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.21 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.18 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,685.13 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Oiknine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.